Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Nexletol Market Size Forecast: How Big Could The Market Get By 2030?
The nexletol market has witnessed considerable growth recently. Its value is expected to expand from $3.21 billion in 2025 to $3.65 billion in 2026, at a compound annual growth rate (CAGR) of 13.8%. This growth observed in prior periods can be linked to factors such as limited options for cholesterol-lowering drugs, the widespread occurrence of hyperlipidemia, a strong reliance on statin treatments, an uptick in hospital and clinic prescriptions, and increased understanding of cardiovascular health risks.
The nexletol market size is anticipated to experience substantial growth over the next few years. Its value is projected to reach $6.07 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This expansion during the forecast period is largely driven by the introduction of bempedoic acid-based therapies, the broadening of homecare and long-term care for medication delivery, a rising incidence of cardiovascular diseases, an increased focus on combination therapies, and the expanding healthcare infrastructure in emerging markets. Noteworthy trends expected in the forecast period encompass a greater adoption of LDL-C lowering therapies, an increasing preference for oral administration over injectable forms, the expansion of cardiovascular disease awareness initiatives, enhanced availability through both prescription and over-the-counter channels, and the integration of homecare and long-term care settings for medication use.
Get A Free Sample Report With In-Depth Market Insights:
Nexletol Market Expansion Drivers: What’s Shaping Future Growth?
The nexletol market is anticipated to expand due to the rising incidence of cardiovascular diseases. These conditions encompass a range of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The increase in cardiovascular diseases is primarily driven by increasingly sedentary lifestyles, where a lack of physical activity leads to weight gain, metabolic imbalances, and higher blood pressure, all of which significantly elevate heart disease risk. Nexletol proves beneficial for cardiovascular diseases by lowering low-density lipoprotein (LDL) cholesterol levels, which in turn helps reduce plaque buildup in arteries and mitigates the risk of heart attacks and other cardiovascular events. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Consequently, the increasing cases of cardiovascular diseases are poised to boost the growth of the nexletol market.
Nexletol Market Segment Landscape And Growth Outlook
The nexletol market covered in this report is segmented –
1) By Type: 180mg, Other Types
2) By Administration Route: Oral, Injectable, Intravenous
3) By Indication: Hyperlipidemia, Atherosclerosis, Cardiovascular Disease
4) By End User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By 180 mg: Prescription-based, Over-The-Counter (OTC), Hospital or clinic use, Long-Term care facilities use
2) By Other Types: 40 mg, 80 mg, Other doses
Nexletol Market Strategic Trends: What Defines The Next Growth Phase?
Major companies operating in the nexletol market are increasingly focusing on developing innovative oral non-statin LDL-cholesterol lowering therapies, such as bempedoic acid-based agents, to address the growing demand driven by the limitations of statins. Bempedoic acid–based agents are oral cholesterol-lowering drugs that inhibit ATP citrate lyase (ACL), an enzyme involved in the liver’s cholesterol-production pathway, thereby reducing LDL cholesterol; they help patients, especially those who cannot tolerate statins, by lowering LDL-C through a liver-selective mechanism that avoids the muscle-related side effects often associated with traditional statins. For instance, in March 2024, Esperion Therapeutics, Inc., a U.S.-based biopharmaceutical company, received FDA approval for a broad label expansion of its drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid + ezetimibe), enabling their use for cardiovascular risk reduction and LDL-C lowering in both primary and secondary prevention regardless of statin use. Nexletol is a once-daily oral tablet formulated with bempedoic acid; it inhibits ACL to lower LDL-C and inflammation, has demonstrated reductions in major cardiovascular events in the CLEAR Outcomes trial, and offers a differentiated, non-statin oral alternative with a favorable safety profile. The updated label significantly widens U.S. patient eligibility, strengthening market adoption.
Nexletol Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the nexletol market are Esperion Therapeutics Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati S.p.A., Almirall S.A., Menarini Group, Les Laboratoires Servier, Torrent Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Hetero Drugs Limited, Alkem Laboratories Limited, Wockhardt Limited, Mylan (Viatris Inc.), Teva Pharmaceutical Industries Limited, Apotex Inc., Hikma Pharmaceuticals PLC, Krka d.d., STADA Arzneimittel AG, Sandoz International GmbH
View The Full Nexletol Market Report:
Nexletol Market Geographic Spread And Regional Opportunities
North America was the largest region in the nexletol market in 2025. The regions covered in the nexletol market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model